Stock Alert for Fibrocell Science Inc. (FCSC)
  • Stock Report for Cell Therapeutics Inc. (CTIC)
  • Stock Report for LifeVantage Corp. (LFVN)
  • " />

    Stock Report for Cannabis Science Inc. (CBIS)

    Cannabis Science Inc. (CBIS) is in the business of developing pharmaceutical grade medical cannabis (marijuana) products. The Company is working with scientific experts on phytocannabinoid science targeting critical illnesses; adhering to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, CBIS is dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

    Share Statistics (05-Mar-12) FY2009 FY2010 % Chg Q32010 Q32011 % Chg
    Symbol CBIS Revenue, $Mn 0.00 0.00 0.00 0.00
    Current price $0.15 Gross marg.
    52wk Range: $0.01-$0.25 Oper. margin -196317.5% -74340.5%
    Avg Vol (3m): n/a Net margin
    Market Cap. 36.29M
    Shares Outstanding 241.92M EPS, $ -0.15 -0.05 -66.7% -0.02 0.00

    Source:, SEC Filings.

    Investment Highlights

    Shares of Cannabis Science (CBIS) advanced nearly 15% to $0.15 in Monday’s trading after the Company on Friday issued market data for its newest over-the-counter products. Over 29 million shares traded hands during the session, versus the 30-day average of 28.82 million. The penny stock has a 52-week range of $0.01 – $0.25.

    Shares of  the medical marijuana company have gained 32.4% in the last five days; 244.0% in the last month; and 81.9% year-to-date.

    CBIS reported that the global anti-aging products market is expected to reach $291.9 billion by 2015, while the U. S. market for anti-aging products for appearance enhancement is expected to reach more than $5 billion by 2015. The Company, citing a new report by Global Industry Analysts, noted that the worldwide cosmeceuticals market stood at $27.2 billion in 2010. The demand for cosmeceutical products is expected to rise 5.8% annually through 2015.

    As stated by CBIS COO Dr. Moe Afaneh, the Company believes its sunscreen and protectant is far superior to others because the company has invested time into understanding what occurs in the body and on the skin, and targeting the cascade of events that occur when people get sunburned. Dr. Afaneh added that CBIS has meticulously targeted key components that lead to sunburn and created its elite formulation so that one instantly feels the skin begin to cool and the pain dissipating.

    Dr. Afaneh also commented on CBIS’s topical skin care products, saying that they help provide relief to various skin conditions such as eczema and other recurring skin irritations. Also, the Company’s anti-aging skin serum, specifically formulated for women, helps rejuvenate and soften the skin, with serum using only natural ingredients including hemp oil extract and many other natural oils and ingredients, he concluded.

    Dr. Afaneh confirmed the newest CBIS brand product line in February, with the Company finalizing negotiations for the manufacturing and national distribution of this new product line.


    Financial Summary

    CBIS had license revenues of $0 and $73,334 for the three and nine month periods ended September 30, 2011, respectively, compared to $0 for both comparative prior year periods. The Company attributed these increases t0 its license deal with Rockbrook signed on August 18, 2010, and the associated recognition of license fees paid by Rockbrook to the Company for the distribution of its products.

    The Company realized a net loss on settlement of liabilities of $873.70K for the three months ended September 30, 2011, an improvement from a net loss of $945.50K reported for the comparable period in 2010.  This decrease was due to the Company issuing more shares for the settlement of less debt and the lower corresponding fair market value of shares issued for settlement. For the nine months ended September 30, 2011, the net loss on settlement of liabilities increased by $822.90K to $3.25 million, compared to $2.42 million for the comparable prior year period. This increase was due to the Company issuing more shares for the settlement of less debt despite the lower corresponding fair market value of shares issued for settlement.

    CBIS’s general and administrative expenses were $463.32K for the three months ended September 30, 2011, down from $1.41 million reported for the three months ended September 30, 2010. The result can be attributed to one-time bonuses for new management consulting agreements signed on July 1, 2010 and increased management and consulting expense from stock issued to consultants for services rendered.

    General and administrative expenses, however, increased by $561.07K to $2.65 million for the nine months ended September 30, 2011, compared to $2.09 million for the nine months ended September 30, 2010. This can be attributed to increased management and consulting expenses, office and laboratory rental expenses.


    Financial Strength (05-Mar-12)




    S&P 500

    Quick Ratio (MRQ) 3.50 1.50 0.65
    Current Ratio (MRQ) 0.00 4.35 1.85 1.00
    LT Debt to Equity (MRQ) 28.81 27.97 171.80
    Total Debt to Equity (MRQ) 31.91 37.64 224.97
    Interest Coverage (TTM) -333.61 49.09 2.43 26.04

    Source:, SEC Filings.

    Technical Analysis


    CBIS is presently near its upper Bollinger Band. This suggests that it is at a high level relative to recent action.

    The MACD for CBIS currently indicates a strong bullish signal for two reasons. First, the MACD is above the signal line, a 9-day moving average. Second, the MACD is above 0, which implies that the underlying moving averages are trending higher.

    Comparative Analysis

    Company Name Ticker Price per Mrkt. Cap. P/E P/S
    Mar05-2012 symbol Share, $ $ Mn 2011 2012 2011 2012
    Bristol-Myers Squibb Co. BMY 32.92 55.54B 16.71 16.97 3.08 3.28
    Medical Marijuana Inc. MJNA 0.07 37.60M n/a n/a n/a n/a
    Cell Therapeutics Inc. CTIC 1.31 240.49M n/a n/a n/a 6.44
    Median       20.29 n/a 3.51 n/a
    Cannabis Science Inc. CBIS 0.15 35.20M n/a n/a n/a n/a

    Source: Thomson Financial

    DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority.  We are neither licensed nor qualified to provide investment advice.

    The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice.  The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities.  We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

    Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company.  An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report.  Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

    Any individual who chooses to invest in any securities should do so with caution.  Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested.  Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

    Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934.  Subscribers are cautioned not to place undue reliance upon these forward looking statements.  These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated.  Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC.  You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

    We are committed to providing factual information on the companies that are profiled.  However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions.  We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so.  Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

    To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).

    We encourage you to invest carefully and read investment information available at the websites of the SEC at and FINRA at

    Leave a Reply

    Your email address will not be published. Required fields are marked *